ScienceNot yet confirmed elsewhere1 publisher2 min readPublished
Yeast fibre in the chow, not the needle: obesity's immune damage looks reversible in mice
A Trinity College Dublin and UCD team says dietary yeast beta-glucan retrained bone marrow progenitors in obese mice, restoring anti-tumour immunity that weight loss alone did not.
The Scientist · Science desk
What happened
- Trinity College Dublin and UCD researchers fed mice standard or high-fat diets with yeast beta-glucan for four to twelve weeks, then challenged them with colorectal, skin and breast cancer cells.
- Helen Roche says it is the first showing that eating yeast beta-glucan alone induces trained immunity by reprogramming bone marrow stem cells, where earlier work needed injections.
- In obese mice the diet restored anti-tumour innate immunity and reversed immune memory defects that had persisted after weight loss.
- The material tested was Wellmune, a food-grade beta-glucan from Kerry Group that is already on sale, published in Cell Reports.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint With no dose, cohort size or tumour-burden figure in the announcement, nobody outside the paper can judge whether obesity's immune deficit was mostly closed or slightly nudged.
- exposure Because the compound is a shelf supplement with a clean safety record, people with cancer or obesity can act on mouse results now, with no human dose and no indication to guide them.
- precedent The named next move is dietary trials in obese, chronically infected and immunocompromised patients, which would put a food ingredient into trial designs aimed at immune recovery rather than weight.
The mechanism is what carries this, not the supplement. Beta-glucan acting on mature myeloid cells near a tumour would need continuous dosing and would fade with the last meal. The Dublin groups report the change one level up, in the bone marrow cells that produce those effectors, which is why they describe the anti-tumour response as stronger and longer-lasting rather than present only while the animals are eating [2]. How a fibre delivered to the gut ends up instructing marrow progenitors is not explained in the announcement [12], and that gap is where the translational risk sits, because an intake in mouse chow is not an intake in a human diet.
The part worth arguing about is what happens after the weight comes off. Obesity's interference with immune function is described in the release as capable of outlasting weight loss [6], which is the version of the problem no referral to a dietitian resolves. Helen Roche, the UCD nutrigenomics professor who co-led the work with Trinity immunologist Frederick Sheedy [8], puts the reversal of that residual defect at the centre of the claim. If it survives replication, obesity-linked immune failure becomes a marrow state with an address rather than a fixed property of the patient.
Read the design closely and the ceiling is visible. Priming came first and the tumour cells arrived afterwards [4], so what was measured is a primed host meeting new cancer cells, not an intervention meeting established disease. That is the easier test, and it is the one that maps least well onto a clinic, where tumours are found rather than scheduled.
On disclosure, the announcement names the tested material and its manufacturer but says nothing about who funded the study or whether a commercial relationship exists [11]. That is not an allegation. It is the line a reader of the eventual human trial will look for first, and it is cheaper to state now than to be asked later.
Breadth also stays inside one mouse model rather than crossing species [10]. That is an ordinary limit for work at this stage, and it is also the exact distance a supplement label will be tempted to skip.
What to watch
- The Cell Reports figures: how much tumour burden differed, in how many animals, at what beta-glucan intake per unit of chow.
- Whether a human trial registers, and who pays for it, given that the tested beta-glucan is a commercial Kerry Group product.
- Whether the training still works when feeding begins after tumours are established rather than before challenge.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence42
- Adoption
- Insufficient
- Hype gap+38
- Incentives66
- Confidence40
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Professor Helen Roche states this is the first demonstration that dietary delivery of yeast beta-glucan is sufficient to induce trained immunity through reprogramming of bone marrow stem cells, and that previous research required injections.
- [2]
The release summary states yeast beta-glucan reprogrammed early immune cells in the bone marrow, leading to stronger, longer-lasting cancer-fighting responses against colorectal, skin and breast cancer cells.
- [3]
The study was published in the journal Cell Reports; the findings were released by Trinity College Dublin and reported on 22 August 2026.
- [4]
Per first author Anna Ledwith, mice were fed a standard or high-fat diet supplemented with yeast beta-glucan for 4 to 12 weeks, and their immune systems were then challenged with colorectal, skin and breast cancer cells; the study also tested whether supplementation could overcome obesity-caused immune dysfunction and whether protective effects persist after weight loss.
- [5]
Roche states the dietary intervention restores anti-tumour innate immunity in obese mice and reverses long-term immune memory defects that persist even after weight loss, which she calls a major unmet clinical challenge.
- [6]
The release states obesity can interfere with immune function, making it harder for the body to respond to tumours, increases susceptibility to infections and cancer, and that these immune changes can continue even after a person loses weight.
- [7]
Sheedy says the yeast beta-glucan used was Wellmune from Kerry Group, which is already food-grade and commercially available, facilitating rapid clinical trials.
- [8]
The study was led by Frederick Sheedy, Associate Professor in Immunology at Trinity's School of Biochemistry and Immunology, and Helen Roche, Professor in Nutrigenomics at UCD and Director of the UCD Conway Institute; Anna Ledwith is first author.
- [9]
The announcement reports no beta-glucan dose, no number of animals and no measured difference in tumour burden; the only quantity given is the 4 to 12 week feeding window.
- [10]
All reported results are in mice: one species, three tumour cell types.
- [11]
The announcement contains no statement of study funding and no statement of any commercial relationship between the researchers and the supplier of the tested beta-glucan.
- [12]
The announcement does not describe the pathway by which orally delivered beta-glucan reaches or signals to bone marrow progenitors.
- [13]
Professor Frederick Sheedy says the research paves the way for dietary intervention studies in people living with obesity, chronic infections and other immunocompromised populations.
- [14]
Yeast beta-glucan is already sold as a dietary supplement and has a strong safety record, which the release says makes it a practical candidate for future studies in people.
Sources
1 independent publisher whose own reporting we read for this story.
- sciencedaily.comThis yeast supplement may boost cancer-fighting immunity
1 article · August 22, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
Entities
- Trinity College DublinFollow
- University College DublinFollow
- Cell ReportsFollow
- Frederick J. SheedyFollow
- Helen M. RocheFollow
- Anna E. LedwithFollow
- WellmuneFollow
- Kerry GroupFollow
- Yeast beta-glucanFollow